Strata Critical Medical

Strata's acquisition of Ohio Valley Perfusion Associates reflects our disciplined approach to M&A: accretive bolt-ons in fragmented, recurring-revenue end markets that complement our existing clinical operations. Cardiac perfusion remains a core growth pillar alongside our organ recovery and transplant vertical. Today's Press Release: ir.stratacritical.com/news-events/pr… $SRTA

Groundbreaking research from the University of Pittsburgh shows liver transplant recipients trained to accept donor organs without lifelong immunosuppression. A small study, but a massive signal for the future of transplant medicine. Every advance in transplant outcomes starts with a successful recovery and delivery. That's what we do. nytimes.com/2026/04/17/hea…

Strata is releasing Q1 2026 earnings on May 6th before market open and will hold a call to discuss the results at 8 am ET (link below). If you have questions, we would love to hear from you! Please send them to investors@srta.com, and management will pick several to answer during the call. register-conf.media-server.com/register/BI799…

Check out the link below for a replay of Strata Critical Co-CEO Will Heyburn's discussion with analyst Matt Shea at the 25th Annual Needham Healthcare Conference. summitcast.meetmax.com/view/cCMfZsH5Z…

Strata Critical Medical today announced that management will present at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026, at 1:30 pm ET. A webcast of the event will be available through the link below. summitcast.meetmax.com/view/cCMfZsH5Z…

Approximately 5,000 Americans die every year while waiting for an organ transplant match. Dr. Montgomery, director of the NYU Langone Transplant Institute—himself a heart transplant recipient—is working to change that with gene-edited pig kidneys. This is what "Reimagining the Future of Organ Transplants" looks like. We're proud to support NYU Langone with logistics, organ recovery services, and organ placement. time.com/collection/tim…

Strata Critical congratulates New England Donor Services on an extraordinary 2025, enabling 1,692 life-saving transplants through innovation, dedication, and operational excellence. We are proud to partner with NEDS, supporting donation opportunities that utilize Normothermic Regional Perfusion (NRP). businesswire.com/news/home/2026…

LiveOnNY, the Greater New York area OPO, launched a campaign to increase organ donation registration. Strata is a proud partner of New York's largest transplant centers. prnewswire.com/news-releases/….

New research from NYU Langone surgeons highlights the increasing number of DCD donors (donation after circulatory death) and the key enablers including normothermic regional perfusion and machine perfusion. nyulangone.org/news/more-orga…

Strata 4Q 2025 organic revenue and gross profit growth of 35% and 39% respectively. Full year 2025 revenue and Adj EBITDA both beat the high end of our guidance range. Raising 2026 revenue and Adj EBITDA guidance. We will host a conference call at 8am ET. edge.media-server.com/mmc/p/ecv47gx3/

Strata will report 4Q 2025 and full year 2025 results this coming Tuesday March 3rd at 8am ET. If you have a question, we would love to hear from you! Please send your questions to investors@srta.com and management will select several to address on Tuesday's call.

Great to see so many turn out for Strata's inaugural Investor Day! If you missed the live webcast, not to worry: catch the replay below $SRTA edge.media-server.com/mmc/p/3tauswyr/

Our Investor Day is tomorrow, Monday 11/17 at 2pm ET. Register for the webcast at the link below. If you have questions, we'd love to answer them! Email us at investors@srta.com before or during the event and we'll cover as many as we can. $SRTA edge.media-server.com/mmc/p/3tauswyr/

Accelerating growth for Strata in Q3 2025: Revenue +37% y/y (+29% organic) with record Adj. EBITDA Profit. Raised 2025 guidance. Read more here: ir.stratacritical.com/news-events/pr…

We are looking forward to our first earnings call as Strata Critical this coming Monday, 11/10 at 8am ET. If you have a question, we would love to hear from you! Please send your questions to investors@srta.com and management will select several to answer on Monday's call.

We're looking forward to our first Investor Day on November 17 at 2pm in New York City! $SRTA Register here: edge.media-server.com/mmc/p/3tauswyr/

Very exciting that the OrganOx metra is now approved to perfuse livers in flight! We stand ready to support our customers and partners at OrganOx in this important mission. @organ_ox $srta globenewswire.com/news-release/2…